Latest Headlines

Latest Headlines

Debiotech partners with Swiss academics to create a novel artificial pancreas

Swiss med tech player Debiotech has partnered to develop a next-gen artificial pancreas for diabetics with a pair of Swiss research centers. The aim is to improve upon the accuracy of automatic insulin delivery by using a microelectromechanical system to control the pump. It will be based on an algorithm designed to estimate patient needs based on their measured glucose levels, the time of day and anticipated activities to adjust the infusion rate from an insulin pump.

*NSYNC's Joey Fatone lends pearly whites to Colgate diabetes campaign

Joey Fatone knows a thing or two about Type 2 diabetes. The performer, who is best known for his run in 90s boy band *NSYNC, has a father with the disease and has already led awareness efforts. Now toothpaste maker Colgate is signing onto Fatone's star power, selecting the celeb to spearhead its diabetes education campaign with the American Diabetes Association.

Omada Health trumpets promising results from study of digital health program in Medicare patients

Omada Health has revealed promising results from a study that looked at how well its digital health tools could help spur weight loss among Medicare members, a milestone for the company a couple of months after it roped in new funding to develop its health management program.

J&J unveils the first major blood glucose monitor to support Apple HealthKit

Blood glucose monitor manufacturers are working to make their data easily accessible and analyzable by patients and healthcare providers. But that's a tall order for this industry segment, which has historically been focused on making tracking easier, cheaper and more convenient rather than more useful.

Fractyl gains traction with balloon ablation device for Type 2 diabetes

As scientists target gastrointestinal tract procedures as a way to treat Type 2 diabetes, Fractyl Labs is forging ahead with its balloon ablation device for the disease to cash in on the trend.

No exodus from DPP-4s on Jardiance CV data, but SGLT2 scripts are shifting: Merck

The good news for Merck & Co.'s Januvia and other DPP-4 diabetes fighters: So far, there's no evidence that doctors or patients are jumping ship for SGLT2 meds, a newer class where Eli Lilly & Co. and Boehringer Ingelheim recently posted impressive cardiovascular data.

Medtronic launches smartphone app enabling diabetics to remotely monitor their condition

Medtronic just launched a smartphone app enabling diabetes patients on its MiniMed continuous glucose monitor to view critical data remotely via their smartphone.

Intestinal resurfacing procedure to treat diabetes shows promise in early stage trial

Fractyl announced that 39 Type 2 diabetes patients treated using its investigative minimally invasive Revita Duodenal Mucosal Resurfacing System exhibited a reduction in blood sugar levels, mirroring the outcomes achieved via invasive bariatric surgery procedures.

Philips, Salesforce develop diabetes app, system to marry consumer and medical data

Royal Philips aims to roll out a series of programs for chronic diseases that marry consumer-oriented device data with the electronic medical record. The idea is to give patients and healthcare providers access to all the relevant data and analysis to improve self-care and medical care.

Sanofi's combo med LixiLan ready to go to FDA in ongoing scramble for diabetes dominance

Sanofi's diabetes franchise faces attack on multiple fronts, with its top-selling Lantus soon to go up against biosimilar competition and several meds facing stepped-up pricing pressures--not to mention new rivals from Eli Lilly & Co. and Novo Nordisk either already launched or on their way. But the French drugmaker has racked up another set of positive data on a new combo med that could help fortify its sales.